1.00
+0.0784(+8.54%)
Currency In USD
| Previous Close | 0.92 |
| Open | 0.93 |
| Day High | 1.02 |
| Day Low | 0.92 |
| 52-Week High | 2.38 |
| 52-Week Low | 0.6 |
| Volume | 577,879 |
| Average Volume | 922,061 |
| Market Cap | 48.35M |
| PE | -0.61 |
| EPS | -1.62 |
| Moving Average 50 Days | 1.44 |
| Moving Average 200 Days | 1.24 |
| Change | 0.08 |
If you invested $1000 in Werewolf Therapeutics, Inc. (HOWL) since IPO date, it would be worth $61.88 as of December 04, 2025 at a share price of $0.996. Whereas If you bought $1000 worth of Werewolf Therapeutics, Inc. (HOWL) shares 3 years ago, it would be worth $569.31 as of December 04, 2025 at a share price of $0.996.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mous
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
GlobeNewswire Inc.
Oct 08, 2025 12:00 PM GMT
Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering the development of therapeutics
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
GlobeNewswire Inc.
Oct 03, 2025 1:00 PM GMT
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to s